 |
|
|
| |
Pooled Resistance Analyses of Darunavir (DRV) Once-daily (QD) Regimens and Formulations Across 10 Clinical Studies of
Treatment-naïve (TN) and Treatment-experienced (TE) Patients With Human Immunodeficiency Virus (HIV)-1 Infection
|
| |
| |
IDWeek, October 2-6, 2019, Washington, DC
Reported by Jules Levin
Erkki Lathouwers,1 Sareh Seyedkazemi,2 Donghan Luo,3 Kimberley Brown,3 Sandra De Meyer,1 Eric Y. Wong2
1Janssen Infectious Diseases BVBA, Beerse, Belgium; 2Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 3Janssen Research & Development, LLC, Titusville, NJ, USA.
|
| |
|
|
|
|
|
